INTRODUCTION
The Hippo pathway was first characterized in Drosophila mosaic genetic screens (1) (2) (3) . It regulates organ size by controlling cell proliferation, differentiation, and survival (4, 5) . Subsequent genetic studies have revealed that Yki, the fly homolog of mammalian YAP, is a major target of the Hippo pathway. Overexpression of Yki induces cell growth and inhibits apoptosis by promoting transcription of diap1 and cycE (6) . On the other hand, Yki is inactivated by Wts-mediated phosphorylation (6) . Specifically, Hippo signaling results in phosphorylation of Yki at multiple sites, inactivating its oncogenic activities. Accordingly, Yki S168A which harbors a mutation in the key phosphorylation site is constitutively active (3, 6) . Eye-specific overexpression of Yki S168A had led to enormous overgrowth of the eye, analogous to the phenotype resulting from knockdown of Hippo kinases (5) . Together, these results demonstrate that Yki is an oncoprotein.
The mammalian homolog of Yki was initially identified as Yes-associated protein (YAP) (7) . YAP contains WW domains capable of interacting with a PPXY motif and a PDZ-binding motif (Post-synaptic density, Discs large, Zonula occludens-1-binding motif) at the C-terminus (8) . It is expressed as two alternatively spliced isoforms: YAP-1 and YAP-2 (9) (Fig. 1) . TAZ (transcriptional coactivator with PDZ motif) was initially identified through its ability to interact with 14-3-3 proteins (10) . TAZ, a YAP homolog, also contains a conserved WW domain that interacts with the PPXY motif as well as the PDZ domain. Consequently, YAP and TAZ have similar structures and functions (8) (Fig. 1) . Yap-knockout mice have exhibited Fig. 2 . Summary of signaling pathways that regulate interactions between YAP and its partners. SMADs activated by TGF-β translocate into the nucleus and bind to YAP, thus promoting the expression of target gene. TEAD is a representative transcription factor that binds to YAP and promotes cell proliferation. YAP is inactivated by LATS kinase which is activated by MST or inactivated by TRIO-RAC1 signaling. In DNA damage, YAP phosphorylated by c-ABL binds to p73 in the nucleus and promotes apoptosis. YAP-ERBB4 activated by NRG1 regulates cell growth by promoting the expression of target genes, including CTGF, CYR61, and ANKRD1. early embryonic lethality (11). ApoE/rtTA-driven liver-specific overexpression of Yap has resulted in hepatomegaly at early stage that ultimately progresses to hepatocellular carcinoma (HCC) at later time points (5) . The oncogenic activity of YAP has been further confirmed in various cultured cell lines. For example, high YAP activity promotes the proliferation and survival of cultured ovarian cancer cells (12). It increases the invasiveness of non-small-cell lung cancer cell lines (13). Conversely, knockdown of YAP suppresses invasion and metastasis in gastric cancer cell lines (14). Similarly, TAZ contributes to tumorigenesis of breast cancer cells by promoting cell migration, invasion, and anchorage-independent growth (15).
YAP/TAZ shuttles between the nucleus and cytoplasm depending on extracellular signaling and growth conditions. For example, YAP is phosphorylated and localized to the cytoplasm at high cell density. However, it is de-phosphorylated and localized to the nucleus at low cell density (3). Such cell density-dependent regulation of YAP phosphorylation is controlled by LATS kinase which is inhibited by GPCR/Gprotein signaling (16) or activated by MST1/2 (Fig. 2) (48, 49) , medulloblastoma (50) , and mesothelioma (51) . In ovarian cancer initiated cells (OCICs), high expression of TEAD1/3/4 is associated with elevated expression of YAP/TEAD target genes such as RUNX2, ITGB2, and ERBB4 (52) . In HCC, dominant-negative TEAD potently suppresses YAP-mediated hepatomegaly and tumorigenesis, indicating that the YAP-TEAD complex plays critical roles in cellular transformation (49) .
The transforming activity of TEADs is disrupted by mutations that abolish the YAP-TEAD interaction. Chen et al. have shown that K297A, W299A, F337A, and Y429A mutations of TEAD4 can disrupt its interaction with YAP and abrogate YAP-TEAD4-mediated transformation of MCF10A cells (53) . Disruption of YAP-TEAD4 interaction is genetically linked to Sveinsson's chorioretinal atrophy (SCRA), an autosomal dominant eye disease characterized by bilateral chorioretinal degeneration (54) . All SCRA patients harbor the Y421H point mutation in TEAD1 (corresponding to Y429 of TEAD4) which abolishes the YAP-TEAD1 interaction (55) . Through interactions with TEADs, activated YAP/TAZ will localize to the nucleus and bind to promoters of target genes involved in cell proliferation, growth, and survival (4, 5, 15, 28, 56) . Target (63) by inducing BAX and p53AIP1 (64) . Binding domains for YAP-p73 interaction have been mapped to the WW domain of YAP and the PPPY motif of p73 (21). The PDZ-binding motif of YAP is required for stabilization of p73 and for p73-mediated pro-apoptotic activity of YAP (65) . The YAP-p73 complex stabilizes p73 and prevents its ITCH-mediated degradation (65) . The interaction between p73 and ITCH is mediated through the PPPY motif of p73 and the WW domain of ITCH (66) . The PPPY motif of p73 is recognized by both YAP and ITCH, consistent with the idea that YAP competes with Itch for binding to p73, thus inhibiting ITCH-mediated ubiquitination of p73 (67) .
The activity of the p73-YAP complex is controlled by multiple mechanisms. Promyelocytic leukemia (PML) promotes the apoptosis-inducing activity of the complex by associating with the p73-YAP complex. PML promotes p300-mediated acetylation of p73 and inhibits YAP degradation via the ubiquitin-proteasome pathway (64, 68, 69) . Upon treatment with interferon-β (IFN-β), PML is induced, thus promoting accumulation of YAP-p73 in the nucleus (70) . Therefore, YAP functions as a tumor suppressor when it is complexed with p73.
The YAP-p73 complex formation and complex-mediated transcription are enhanced by c-ABL (71) . In multiple myeloma, YAP is deleted or consistently downregulated to evade apoptosis despite pervasive DNA damage (71) . Re-expression of YAP in multiple myeloma cells induces c-ABL-mediated apoptosis and reduces cell proliferation. These results cause the formation of p73-YAP complex by c-ABL (71) . In response to DNA damage, c-ABL is activated. It then phosphorylates YAP on residue Y357 (72) (Fig. 2) . The resultant phospho-Y357 YAP accumulates in the nucleus (72) . In the nucleus, YAP interacts with p73 and induces pro-apoptotic target genes such as BAX and PIG3 (73) . Notably, c-ABL-mediated YAP phosphorylation causes dissociation of other YAP partners to facilitate formation of the YAP-p73 complex. In particular, c-ABL dissociates both RUNX and ITCH from YAP (72) . Thus, c-ABL dictates the binding partner of YAP by controlling its phosphorylation status. It acts as a "switch" between different transcriptional programs, i.e., between oncogenic and tumor-suppressor functions of YAP. The Y357 residue of YAP is a potential phosphorylation target for several other tyrosine kinases, including Yes and Src. This indicates that these kinases may also affect the choice of YAP partner (72, 74, 75) . YAP-TEAD interaction is also affected by LATS1/2-mediated phosphorylation. Therefore, the identity of YAP-binding partner might be affected by these kinases.
ERBB4
ERBB-4 (EGFR family member v-Erb-b2 avian erythroblastic leukemia viral oncogene homolog 4) receptor protein tyrosine kinase is proteolytically processed by membrane proteases (γ-secretase) in response to ligand or 12-O-tetradecanoylphorbol-13-acetate stimulation. The resultant soluble intracellular domain (ICD) of ERBB-4 is translocated to the nucleus, functioning as a transcription regulator (22) (Fig. 2) .
The ICD of ERBB4 is a binding partner of YAP. ERBB4 co-immunoprecipitates with YAP and TEAD that might form a ternary complex. Accordingly, ERBB4 could either aid the assembly of binary YAP-TEAD complex or participate in ERBB4/YAP/TEAD ternary complex. In the latter scenario, ERBB4 could modulate transcription at TEAD target sites by recruiting or displacing transcription factors (22, 76, 77) . The interaction between YAP and ERBB4 is mediated through WW domains of YAP and PPXY motifs located within the ICD of ERBB4 (78) . YAP-ERBB4 regulates organ and tissue growth by promoting the expression of target genes, including CTGF, CYR61, and ANKRD1 (77) . YAP-ERBB4 is activated by NRG1 (a member of the neuregulin family that acts on the EGFR family of receptors). This activation is inhibited by the Hippo pathway (77) .
The YAP-ERBB4 interaction is inhibited by WW domain-containing oxidoreductase (WWOX) which contains two WW domains that interact with several binding partners of YAP, such as p73 (79), ERBB4 (80) , and RUNX2 (81). WWOX sequesters ERBB-4 in the cytoplasm and antagonizes the function of YAP (82) . WWOX is frequently inactivated in osteosarcoma. Restoration of WWOX osteosarcoma cell lines decreases the expression of YAP-RUNX2 target genes involved in cell adhesion and motility (83) . Thus, WWOX modulates YAP activity by competing with YAP for binding to p73, ERBB4, and RUNX2. The association between YAP and ERBB4 suggests the existence of cross-talk between EGFR and Hippo-YAP networks because ERBB4 is a key member of the 
TBX5
YAP, β-catenin, and TBX5 form a complex and induce the expression of transcriptional targets such as BCL2L1 and BIRC5. This complex is required for the survival and transformation of β-catenin-active cancer cell lines (74) . TAZ directly interacts with TBX5, p300, and PCAF, thereby acting as a central component in TBX5-dependent transcriptional complexes. TAZ-related protein YAP also stimulates TBX5 activity. Its influence on TBX5 is potentiated by TAZ, with which it forms a heterodimer (85). TBX5 recruits TAZ/YAP to downstream target genes, resulting in remarkable augmentation of transcription. Physical association of TAZ with p300 and PCAF stimulates TBX5-dependent transcription presumably by promoting acetylation of histones associated with TBX5 target genes (85) .
SMADs
SMADs are intracellular proteins that transduce extracellular signals from TGF-β or BMP to the nucleus where they activate transcription of downstream target genes (86) . SMADs phosphorylated by receptor kinases form trimers of two receptor-regulated SMADs (Smad1, 2, 3, 5, 8) and one co-SMAD (SMAD4). SMAD6 and 7 are inhibitory SMADs that attenuate TGF-β and BMP signals. YAP/TAZ also regulate TGF-β-SMAD signaling by dictating the localization of receptor-activated SMADs in response to polarity complexes formed in response to cell density (87-89) (Fig. 2) . At low cell density, YAP/TAZ and SMAD2/3 accumulate in the nucleus. By contrast, at high density, the Hippo pathway drives cytoplasmic localization of YAP/TAZ which sequesters SMAD2/3, thereby suppressing TGF-β signaling (3, 88) . SMAD7 also interacts with YAP and increases the inhibitory activity of SMAD7 against TGF-β signaling (26). In the nucleus, TAZ forms a complex with SMAD2/3-SMAD4 and couples the complex to the transcriptional machinery (87, 88) . This complex in turn binds to promoters of SMAD7 and plasminogen activator inhibitor 1 (PAI-1) genes to activate their transcription (87) . Because SMAD7 is inhibitory, as noted above, activation of SMAD7 transcription by the SMAD2/3-SMAD4 complex suppresses TGF-β signaling (86) .
RUNXs
RUNX family members are DNA-binding transcription factors that serve as master regulators of development. Among three RUNX family members (RUNX1, RUNX2, and RUNX3), RUNX2 functions as an osteogenic master regulator that governs skeletal development and homeostasis (90, 91 (94) . This complex represses PPARγ-dependent gene transcription (94) . RUNX3 interacts with YAP and TEAD4 to form a YAP-TEAD4-RUNX3 ternary complex. RUNX3 interacts with TEAD4 through the C-terminal region of TEAD4 and the Runt domain of RUNX3. However, RUNX3 interacts with YAP through the WW domain of YAP and the PPPY motif of RUNX3. The pattern of YAP-TEAD4-RUNX3 ternary complex formation is very similar to that of the YAP-TEAD-ERBB4 ternary complex (77) . Notably, association of RUNX3 with YAP-TEAD4 markedly decreases the DNA-binding ability of TEAD (24). Consistent with this, ectopic expression of RUNX3 in a gastric cancer cell line also attenuates the oncogenic activity of YAP-TEAD4 (24). Conversely, expression of RUNX3-R122C (mutated RUNX3 at Arginine 122 to Cysteine, previously identified in gastric cancer (95) ) impairs the interaction between RUNX3 and TEAD (24). Thus, RUNX3 antagonizes the oncogenic activity of YAP-TEAD4.
Jang et al. have reported that the interaction between YAP and RUNX3 is promoted when cell growth is inhibited (96) . When cells are grown at high density or cultured under serum-starved conditions, LATS1/2-mediated YAP phosphorylation is elevated. In addition, RUNX3 interacts with http://bmbreports.org Fig. 3 . Reciprocal regulation of YAP activity by TRIO-RAC1 signaling and the Hippo pathway. RUNX3 interacts with YAP and TEAD4 to form a YAP-TEAD4-RUNX3 ternary complex. When TRIO-RAC signaling is activated, kinase activity of LATS is inhibited while YAP activity is increased. RUNX3 then dissociates from the ternary complex, resulting in the formation YAP-TEAD complex. When cell growth is inhibited, TEAD dissociates from the ternary complex through LATS-mediated YAP phosphorylation, resulting in the formation YAP-RUNX3 complex. Therefore, LATS1/2-mediated YAP phosphorylation not only inhibits YAP-TEAD complex, but also facilitates YAP-RUNX3 complex formation. phosphorylated YAP (96) . Mutation of LATS1/2-mediated phosphorylation sites in YAP can abolish the YAP-RUNX3 interaction without affecting YAP-TEAD4 interaction. LATS1/2-mediated phosphorylation of YAP causes dissociation of the YAP-TEAD4 complex (Fig. 3) . Thus, YAP phosphorylation status controlled by cell cycle governs the switching of YAP binding between TEAD4 and RUNX3 (96) . It is worth mentioning that the mechanism underlying phosphorylationdependent partner choice is very similar to that of regulation by c-ABL. As noted above, c-ABL-mediated YAP phosphorylation dissociates RUNX and ITCH from YAP, thereby facilitating formation of the YAP-p73 complex (72) . Therefore, the oncogenic or tumor-suppressive activity of YAP is determined by its DNA-binding partner proteins which in turn are governed by cellular status.
PROSPECTS
The role of YAP/TAZ in cancer development remains controversial. Initially, YAP/TAZ were described as oncogenes (6) . Consistent with this, overexpression of YAP induces cell proliferation. In addition, YAP expression is elevated in human HCC and many other malignancies (97) . On the other hand, recent studies have shown that YAP induces apoptosis in response to DNA damage in collaboration with p73 and PML (64) . It also suppresses human colorectal cancer (98) . These observations indicate that YAP could be defined as a tumor suppressor as well as an oncogene. The opposing roles of YAP in oncogenesis might be due to its lack of DNA-binding activity. This feature causes YAP target gene selection to be dictated by its DNA-binding partners which in turn are determined by their phosphorylation status. To further understand the roles of YAP in oncogenesis, it is important to study the molecular partners that interact with YAP as well as the kinases that regulate complex formation. 
